---
title: "Foundayo (orforglipron) in chronic weight management: Specific populations questions"
description: "Specific populations questions on Foundayo (orforglipron) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Foundayo be used during pregnancy? Can Foundayo be used while breastfeeding? Should women use contraception while taking Foundayo? Can children or teenagers take Foundayo? 4 further questions follow. 8 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Foundayo (orforglipron) in chronic weight management: Specific populations questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Foundayo](https://uspl.lilly.com/foundayo/foundayo.html#pi)

## Pregnancy and breastfeeding

<a id="foundayo-pregnancy"></a>

### Can Foundayo be used during pregnancy?

> “Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus and discontinue FOUNDAYO.
>
> There are no adequate and well-controlled studies of FOUNDAYO during pregnancy. Based on animal reproduction studies, there may be risks to the fetus from exposure to orforglipron during pregnancy.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Weight%20loss%20offers%20no%20benefit,exposure%20to%20orforglipron%20during%20pregnancy.)

> “There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to FOUNDAYO (orforglipron) during pregnancy. Pregnant patients exposed to FOUNDAYO and healthcare providers are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=There%20will%20be%20a%20pregnancy,and%20Company%20at%201%2D800%2DLillyRx%20%281%2D800%2D545%2D5979%29.)

<a id="foundayo-breastfeeding"></a>

### Can Foundayo be used while breastfeeding?

> “There are no data on the presence of orforglipron or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Orforglipron was present in the milk of lactating rats in in vivo testing (see Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. FOUNDAYO is not recommended for nursing women. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for FOUNDAYO and any potential adverse effects on the breastfed child from FOUNDAYO or from the underlying maternal condition.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=There%20are%20no%20data%20on,from%20the%20underlying%20maternal%20condition.)

<a id="foundayo-contraception"></a>

### Should women use contraception while taking Foundayo?

> “Based on animal reproduction studies, there may be risks to the fetus from exposure to orforglipron during pregnancy [see Pregnancy (8.1)]. Advise women of childbearing potential to use effective contraception during treatment with FOUNDAYO. The effect of FOUNDAYO on the absorption of oral contraceptives has not been evaluated in a clinical trial. Because delayed gastric emptying may affect the absorption of oral medications, advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 30 days after initiation with FOUNDAYO and for 30 days after each dose escalation [see Drug Interactions (7.3), Clinical Pharmacology (12.3)].”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Contraception-,Based%20on%20animal%20reproduction%20studies%2C%20there%20may%20be%20risks%20to,Interactions%20%287.3%29%2C%20Clinical%20Pharmacology%20%2812.3%29%5D.)

## Specific populations

<a id="foundayo-children"></a>

### Can children or teenagers take Foundayo?

> “Safety and effectiveness of FOUNDAYO have not been established in pediatric patients.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Safety%20and%20effectiveness%20of%20FOUNDAYO%20have%20not%20been%20established%20in%20pediatric%20patients.)

> “It is not known if FOUNDAYO is safe and effective for use in children.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=It%20is%20not%20known%20if%20FOUNDAYO%20is,effective%20for%20use%20in%20children.)

Note: The second passage is from the Medication Guide printed with the Prescribing Information.

<a id="foundayo-older-adults"></a>

### Is Foundayo safe and effective for adults 65 and older?

> “In a pool of Trials 1 and 2, 399 (13%) FOUNDAYO-treated patients were 65 years of age or older, and 33 (1%) FOUNDAYO-treated patients were 75 years of age or older at baseline [see Clinical Studies (14)]. No overall differences in safety or effectiveness of FOUNDAYO have been observed between patients 65 years of age or older and younger adult patients.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20a%20pool%20of%20Trials%201%20and%202%2C%20399,older%20and%20younger%20adult%20patients.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-liver-impairment"></a>

### Does Foundayo need a dose adjustment for liver disease?

> “FOUNDAYO is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C) [see Clinical Pharmacology (12.3)].
>
> No dosage modification of FOUNDAYO is recommended in patients with mild or moderate hepatic impairment (Child-Pugh Class A and B, respectively) [see Clinical Pharmacology (12.3)].”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%20is%20not%20recommended%20for%20use,respectively%29%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

> “Orforglipron AUC(0-∞) increased by 1.7-fold and 4.6-fold in patients with moderate and severe hepatic impairment, respectively, compared to subjects with normal hepatic function. Cmax in patients with moderate and severe hepatic impairment was similar to Cmax in subjects with normal hepatic function [see Use in Specific Populations (8.6)].”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Orforglipron%20AUC%280%2D%E2%88%9E%29%20increased%20by%201.7%2Dfold,Use%20in%20Specific%20Populations%20%288.6%29%5D.)

<a id="foundayo-kidney-impairment"></a>

### Does Foundayo need a dose adjustment for kidney disease?

> “No dosage modification of FOUNDAYO is recommended for patients with renal impairment. In subjects with renal impairment including end-stage renal disease (ESRD), no change in orforglipron pharmacokinetics (PK) was observed [see Clinical Pharmacology (12.3)]. Monitor renal function in patients reporting adverse reactions to FOUNDAYO that could lead to volume depletion [see Warnings and Precautions (5.4)].”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=No%20dosage%20modification%20of%20FOUNDAYO%20is%20recommended%20for,%5Bsee%20Warnings%20and%20Precautions%20%285.4%29%5D.)

<a id="foundayo-overdose"></a>

### What should be done after a Foundayo overdose?

> “In the event of an overdose, consider contacting Poison Control (1-800-222-1222) or a medical toxicologist for latest recommendations. Initiate appropriate supportive treatment according to the patient's clinical signs and symptoms. A period of observation and treatment for these symptoms may be necessary, considering the half-life of orforglipron [see Clinical Pharmacology (12.3)].”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20the%20event%20of%20an,orforglipron%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

## Related pages
- [Medical information: Foundayo (orforglipron): Chronic weight management](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/access-and-coverage)
